SEC Info - Amgen Inc - ‘10-Q’ for 9/30/15

SEC Info℠

Home

Help

Please Sign In

Amgen Inc – ‘10-Q’ for 9/30/15 – ‘EX-101.SCH’

On: Monday, 11/2/15, at 6:09am ET · For: 9/30/15 · Accession #: 318154-15-25 · File #: 0-12477

  As Of               Filer                 Filing    For·On·As Docs:Size

11/02/15  Amgen Inc                         10-Q        9/30/15   76:10M

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    782K 
 2: EX-10.4     Form of Global Rsu Agreement                        HTML    204K 
 3: EX-10.6     Form of Performance Unit Agreement                  HTML    184K 
 4: EX-31       Rule 13A-14(A) Certifications                       HTML     37K 
 5: EX-32       Section 1350 Certifications                         HTML     26K 
52: R1          Document and Entity Information                     HTML     40K 
41: R2          Condensed Consolidated Statements of Income         HTML     83K 
                (Unaudited)                                                      
50: R3          Condensed Consolidated Statements of Comprehensive  HTML     49K 
                Income (Unaudited)                                               
54: R4          Condensed Consolidated Balance Sheets (Unaudited)   HTML     95K 
70: R5          Condensed Consolidated Balance Sheets (Unaudited)   HTML     30K 
                (Parenthetical)                                                  
43: R6          Condensed Consolidated Statements of Cash Flows     HTML    119K 
                (Unaudited)                                                      
49: R7          Summary of significant accounting policies          HTML     33K 
37: R8          Restructuring                                       HTML     89K 
28: R9          Income taxes                                        HTML     33K 
71: R10         Earnings per share                                  HTML     56K 
56: R11         Collaborative arrangements                          HTML     40K 
55: R12         Available-for-sale investments                      HTML    221K 
61: R13         Inventories                                         HTML     32K 
62: R14         Goodwill and other intangible assets                HTML     87K 
59: R15         Financing arrangements                              HTML     77K 
63: R16         Stockholders' equity                                HTML    164K 
51: R17         Fair value measurement                              HTML    220K 
53: R18         Derivative instruments                              HTML    172K 
58: R19         Contingencies and commitments                       HTML     41K 
76: R20         Subsequent event                                    HTML     24K 
66: R21         Summary of significant accounting policies          HTML     47K 
                (Policies)                                                       
46: R22         Restructuring (Tables)                              HTML     88K 
57: R23         Earnings per share (Tables)                         HTML     53K 
48: R24         Available-for-sale investments (Tables)             HTML    221K 
21: R25         Inventories (Tables)                                HTML     31K 
67: R26         Goodwill and other intangible assets (Tables)       HTML     77K 
73: R27         Financing arrangements (Tables)                     HTML     78K 
32: R28         Stockholders' equity (Tables)                       HTML    158K 
31: R29         Fair value measurement (Tables)                     HTML    199K 
35: R30         Derivative instruments (Tables)                     HTML    153K 
36: R31         Summary of significant accounting policies          HTML     26K 
                (Details)                                                        
38: R32         Restructuring (Details Textual)                     HTML     42K 
18: R33         Restructuring (Summary of Charges by Type)          HTML     48K 
                (Details)                                                        
64: R34         Restructuring (Summary of Expenses and Payments)    HTML     36K 
                (Details)                                                        
45: R35         Income taxes (Details)                              HTML     37K 
47: R36         Earnings per share (Details)                        HTML     46K 
24: R37         Collaborative arrangements (Details)                HTML     47K 
75: R38         Available-for-sale investments (Details)            HTML     73K 
12: R39         Available-for-sale investments (Fair Values by      HTML     38K 
                Classification) (Details)                                        
39: R40         Available-for-sale investments (Fair Values by      HTML     44K 
                Contractual Maturity) (Details)                                  
69: R41         Available-for-sale investments (Unrealized Losses   HTML     65K 
                and Fair Values) (Details)                                       
23: R42         Available-for-sale investments (Details Textual)    HTML     32K 
30: R43         Inventories (Details)                               HTML     34K 
34: R44         Goodwill and other intangible assets (Goodwill      HTML     30K 
                Roll Forward) (Details)                                          
42: R45         Goodwill and other intangible assets (Idenfitiable  HTML     53K 
                Intangible Assets) (Details)                                     
17: R46         Goodwill and other intangible assets (Details       HTML     49K 
                Textual)                                                         
27: R47         Financing arrangements (Details)                    HTML    150K 
14: R48         Stockholders' equity (Details Textual)              HTML     35K 
68: R49         Stockholders' equity (Share Repurchase Program)     HTML     29K 
                (Details)                                                        
22: R50         Stockholders' equity (Components of AOCI)           HTML     83K 
                (Details)                                                        
65: R51         Stockholders' equity (Relcassifications out of      HTML     50K 
                AOCI) (Details)                                                  
25: R52         Fair value measurement (Details)                    HTML    167K 
40: R53         Fair value measurement (Changes in Contingent       HTML     32K 
                Consideration Obligation) (Details)                              
13: R54         Fair value measurements (Details Textual)           HTML     60K 
16: R55         Derivative instruments (Cross-currency Swaps)       HTML     43K 
                (Details)                                                        
33: R56         Derivative instruments (Effective Potion of         HTML     30K 
                Unrealized Gain (Loss)) (Details)                                
19: R57         Derivative instruments (Locations and Effective     HTML     47K 
                Potions of Gain (Loss) Reclassified out of AOCI)                 
                (Details)                                                        
72: R58         Derivative instruments (Locations and Gain (Loss)   HTML     28K 
                for Derivatives Not Designated as Hedging                        
                Instruments) (Details)                                           
44: R59         Derivative instruments (Details)                    HTML     54K 
60: R60         Derivative instruments (Details Textual)            HTML     74K 
26: R61         Contingencies and commitments (Details)             HTML     25K 
29: R62         Subsequent event (Details)                          HTML     28K 
74: XML         IDEA XML File -- Filing Summary                      XML    139K 
15: EXCEL       IDEA Workbook of Financial Reports                  XLSX     86K 
 6: EX-101.INS  XBRL Instance -- amgn-20150930                       XML   3.62M 
 8: EX-101.CAL  XBRL Calculations -- amgn-20150930_cal               XML    217K 
 9: EX-101.DEF  XBRL Definitions -- amgn-20150930_def                XML    628K 
10: EX-101.LAB  XBRL Labels -- amgn-20150930_lab                     XML   1.59M 
11: EX-101.PRE  XBRL Presentations -- amgn-20150930_pre              XML    914K 
 7: EX-101.SCH  XBRL Schema -- amgn-20150930                         XSD    181K 
20: ZIP         XBRL Zipped Folder -- 0000318154-15-000025-xbrl      Zip    262K

‘EX-101.SCH’ — XBRL Schema — amgn-20150930

This Exhibit is an XBRL XML File.

<?xml version="1.0" encoding="windows-1252"?>

<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amgen.com/20150930" xmlns:amgn="http://www.amgen.com/20150930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">

<xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>

<xsd:import namespace="http://fasb.org/us-roles/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-roles-2015-01-31.xsd"/>

<xsd:import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>

<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>

<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>

<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>

<xsd:annotation>

<xsd:appinfo>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20150930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20150930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20150930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20150930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>

<link:roleType id="AvailableForSaleInvestments" roleURI="http://www.amgen.com/role/AvailableForSaleInvestments">

<link:definition> 2109100 - Disclosure - Available-for-sale investments </link:definition>

<link:usedOn> link:presentationLink </link:usedOn>